english.prescrire.org > Spotlight > Archives : 2022 > In the July-August issue of Prescrire International: Indacaterol + glycopyrronium + mometasone (Enerzair Breezhaler°) in asthma

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2022 : 1 | 30 | 60

In the July-August issue of Prescrire International: Indacaterol + glycopyrronium + mometasone (Enerzair Breezhaler°) in asthma

FREE DOWNLOAD How do Prescrire's editors rate this new fixed-dose combination? And what about the questions raised by a "connected drug" such as the Enerzair Breezhaler°, with its electronic sensor that can record and transmit various data?
Full text available for free download.

Prescrire's rating

  •  NOTHING NEW  According to two comparative trials, adding glycopyrronium to indacaterol + mometasone dual therapy produces a modest reduction in the risk of exacerbations, but offers no advantages over triple therapy containing tiotropium. Like tiotropium, glycopyrronium mainly has antimuscarinic and cardiac adverse effects. 
EDITORS' OPINION
Collected data (excerpts)
Enerzair Breezhaler°, a product authorised for use in asthma, is marketed with or without an electronic sensor. When attached to the inhaler, this sensor records various details about the doses of the drug which the patient takes.

A few questions come to mind when faced with a "connected" drug, for example:
  • Who are we working for when we collect data?
  • Are these data shared with third parties known to the patient, or perhaps even unknown?
  • How is data security achieved during transmission and storage on various electronic devices (computers, smartphones)?
  • Are they collected for commercial purposes?
  • Are European regulations on the protection of personal data being observed?
Full text available for download below.

 ©Prescrire 1 July 2022

Source: "Indacaterol + glycopyrronium + mometasone (Enerzair Breezhaler°) in asthma" Prescrire International 2022; 31 (239): 181. Free.

Enjoy full access to Prescrire International, and support independent information
Share
Share on Facebook Share on Twitter


Prescrire's rating:

Prescrire's rating
 NOTHING NEW 


Read more:

All the subjects in
Prescrire's Spotlight
Free >